Austin, July 01, 2025 (GLOBE NEWSWIRE) -- Coronary Stent Market Size & Growth Analysis
According to SNS Insider, the global Coronary Stent Market was valued at USD 7.26 billion in 2023 and is projected to reach USD 10.83 billion by 2032, growing at a CAGR of 4.55% during the forecast period 2024–2032. The rising global burden of cardiovascular diseases, coupled with technological innovations in stent design, is propelling market expansion.
The U.S. coronary stent market was valued at USD 4.42 billion in 2023 and is projected to reach USD 7.07 billion by 2032, growing at a CAGR of 5.35% during 2024–2032. Growth is driven by rising coronary artery disease prevalence, high healthcare spending, and rapid adoption of next-gen drug-eluting and bioresorbable stents.
Get a Sample Report of Coronary Stent Market@ https://www.snsinsider.com/sample-request/3437
Major Players Analysis Listed in this Report are:
- Abbott Laboratories (Xience, Absorb, Xpedition)
- B. Braun Melsungen AG (Coroflex ISAR, Coroflex Blue Ultra, Coroflex DEBlue)
- Biosensors International Group, Ltd. (BioMatrix Alpha, BioFreedom, BioMatrix NeoFlex)
- BIOTRONIK SE & Co. KG (Orsiro, Magmaris, PK Papyrus)
- Boston Scientific Corporation (Promus Elite, Synergy XD, REBEL)
- Hexacath (Titan 2, Teneo, TITAN OPTIMAX)
- Lepu Medical Technology (Beijing) Co., Ltd. (*Nano+, Taurus Elite, Taurus II)
- Medtronic PLC (Resolute Onyx, Resolute Integrity, Endeavor)
- Meril Life Sciences Pvt. Ltd. (BioMime Morph, BioMime Branch, MeRes100)
- MicroPort Scientific Corporation (Firehawk, Firebird 2, Foxtrot NC)
- Sahajanand Medical Technologies Limited (Supraflex Cruz, Supraflex Star, Supraflex Trio)
- Shanghai MicroPort Endovascular MedTech Co., Ltd. (Minos, Castor, Aegis)
- STENTYS SA (Xposition S, Xposition R)
- Sino Medical Sciences Technology Inc. (Tetrilimus, BuMA Supreme, BuMA)
- Translumina GmbH (Yukon Choice PC, Yukon Chrome, VIVO ISAR)
- Terumo Corporation (Ultimaster, Ultimaster Tansei, Nobori)
- Vascular Concepts (GenX CrCo, Flexy Rapamycin, Pronova)
- Alvimedica (Cre8 EVO, NiTiDES)
- Balton Medical (Coracto, Alex Plus)
- Essen Technology (BuMA Supreme, BuMA)
Coronary Stent Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 7.26 billion |
| Market Size by 2032 | US$ 10.83 billion |
| CAGR (2024–2032) | 4.55% |
| U.S. Market 2024 | USD 4.42 billion |
| U.S. Forecast by 2032 | USD 7.07 billion |
| Base Year | 2023 |
| Forecast Period | 2024–2032 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
Segmentation Analysis
By Product: Drug-Eluting Stents Dominate, Bioresorbable Coronary Stents Grow Fastest
The Drug-Eluting Stents segment dominated the coronary stent market in 2023 and accounted for 66.7% of revenue share, owing to their higher efficacy in reducing the instances of restenosis and the interventions required after the operation. The clinical data supporting them and continuous improvement in polymer coating and antiproliferative drug agents also make them a practical choice.
The Bioresorbable Coronary Stents segment is projected to register the fastest CAGR during the forecast period. This growth is driven by the increasing demand for bioresorbable stents, which dissolve shortly after normal blood flow is restored, while avoiding long-term problems with permanent implants, is fuelling this growth. The better results of clinical trials and wider regulatory approvals will boost adoption.
By Mode of Delivery: Balloon-Expandable Stents Dominate and Grow Fastest
Balloon-expandable stents held the dominant share in 2023 and are projected to maintain their lead throughout 2024–2032. With their unique ability to be located and the exceptional radial strength they possess, they are perfect for the majority of the coronary procedures, particularly in the case of stable lesions. These stents are now favored in the elective setting where only mild contortions of the vessel are induced. In addition, technological upgrades have also resulted in more accurate deployments and successes in the procedure itself. The rapidly growing segment is balloon-expandable stents, credited to their usability with complex anatomies, ease-of-use, and the preference for elective PCI procedures among interventional cardiologists, particularly in urban healthcare settings.
By Material: Metallic Stents Dominate, Cobalt Chromium Stents Grow Fastest
The metallic stents segment dominated the market in 2023 and accounted for 33.8% of revenue share, owing to their mechanical strength, cost-effectiveness, and long-standing use in clinical practice. They provide high deliverability and radiopacity to facilitate their accurate deployment and observation during the intervention. This segment includes devices based on stainless steel and other alloys, which have been proven to reliably perform.
Cobalt Chromium stents are expected to witness the fastest CAGR from 2024 to 2032. Depending on the degree of improvement in flexibility and biocompatibility, their thin struts make them very appropriate for complex interventions and especially in tortuous vessels. Moreover, their lighter weight makes them easier to deliver and offers improved recovery after the procedure.
By End User: Hospitals Dominate, Ambulatory Surgical Centers Grow Fastest
Hospitals dominated the end-user segment in 2023 and accounted for 55.4% of revenue share, as a result of infrastructure enabling complex cases to be treated with emergency support and the availability of trained staff. Such institutions are frequently first in line for new technologies and partnerships with top-flight cardiovascular research programs.
Ambulatory Surgical Centers (ASCs) are expected to register the fastest growth during 2024–2032, due to their cost-efficiency, shorter hospital stays, and an increase in outpatient elective PCI procedures. With the rapid development of imaging and surgical equipment, ASCs have also become an attractive alternative for low-to-moderate risk patients. They are also gaining additional popularity owing to their lucrative reimbursement and fewer procedural delays.
For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https://www.snsinsider.com/request-analyst/3437
Coronary Stent Market Segmentation
By Product
- Bare Metal Stents
- Drug Eluting Stents
- Bioresorbable Vascular Scaffolds (BVS)/Bioresorbable Coronary Stents
- Others
By Mode of Delivery
- Balloon-expandable Stents
- Self-expanding Stents
By Material
- Metallic Stents
- Cobalt Chromium
- Platinum Chromium
- Nickel Titanium
- Stainless Steel
- Others
By End User
- Hospitals
- Cardiac Centers
- Ambulatory Surgical Centers
By Region: North America Dominates, Asia-Pacific Grows Fastest
North America dominated the coronary stent market in 2023 and accounted for 38.5% of revenue share, primarily attributed to a high prevalence of coronary artery disease, favorable reimbursement policies, as well as a well-established presence of the major market players. It is also continents ahead in technology embracement, clinical research, and catheterization skills. North America benefits from the sustained competitive advantage associated with a strong medical device manufacturing presence, and U.S.-based companies are key contributors to the global pipeline of new stent designs.
The Asia-Pacific region is forecasted to grow at the fastest CAGR from 2024 to 2032, increasing healthcare expenditure, quickly growing urbanization, growth in patient population, and government initiatives to boost access to advanced cardiac care services in countries like China, India, and South Korea. Owing to the increasing medical tourism and public-private investment programs, further aid to the growth of the regional market.
Recent Developments:
In January 2024, Abbott announced its launch of the next-generation XIENCE Sierra Everolimus-eluting coronary stent, featuring enhanced design and delivery system for Indian markets. The stent is CE-marked and aims to improve procedural precision and patient outcomes in complex coronary cases
In March 2024, Boston Scientific’s latest-generation Synergy XD everolimus-eluting platinum chromium coronary stent system, built on a bioabsorbable polymer platform, received regulatory CE mark approval in 2024, opening its rollout across European markets.
Buy a Single-User PDF of Coronary Stent Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/3437
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Coronary Stent Market by Product
8. Coronary Stent Market by Mode of Delivery
9. Coronary Stent Market by Material
10. Coronary Stent Market by End User
11. Regional Analysis
12. Company Profiles
13. Use Cases and Best Practices
14. Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
